An Australian stem cell and regenerative medicine company

March 05, 2024

Cynata Therapeutics treats first patient in aGvHD clinical trial

In early March, the first patient was enrolled and treated in Cynata’s Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD).

Learn more here:

February 26, 2024

Cynata say their diabetic foot ulcer trial is going great guns

Cynata has updated the market on the positive progress of its diabetic foot ulcers clinical trial.

Read Stockhead’s coverage here 

December 28, 2023

Cynata expects DFU trial results in Q1 2024

Cynata is analysing wound surface areas in the first 16 patients of its Phase 1 trial for CYP-006TK, its off-the-shelf iPSC-derived MSC topical dressing for diabetic foot ulcers, with results expected by Q1 2024.

Understand more here

December 07, 2023

Approval to launch phase two trial of CYP-001 in Turkey

Following regulatory and ethics clearance to initiate a Phase 2 clinical trial for CYP-001 in patients with High-Risk acute Graft versus Host Disease at clinical sites in Turkey, Cynata plans to establish multiple clinical centers, commencing site initiation visits in the next 1-2 months. 

Read more here

November 16, 2023

Proactive Investors interview

Following the completion of the site initiation visit at Weill Cornell Medical Center in New York for the Phase 2 clinical trial of CYP-001 in High-Risk acute Graft versus Host Disease (HR-aGvHD), Dr Kilian Kelly spoke with Proactive Investors about this important milestone. 

Watch the interview here